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1 Drug description 
Generic/Brand name:  
Rituximab/Rituxan® (United States, Japan, Canada), MabThera® (rest of 
the world) 
Developer/Company:  
Genentech, Inc., and Biogen Idec. co-market MabThera in the United States. 
Chugai Pharmaceutical and Zenyaku Kogyo Co. Ltd. co-market MabThera 
in Japan. Hoffmann-La Roche Ltd. markets MabThera in the rest of the 
world [1].  
Description: 
Rituximab belongs to the pharmacotherapeutic group of antineoplastic 
agents and monoclonal antibodies (ATC code: L01XC02) [2]. 
Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody 
targeted against the cluster of differentiation (CD) 20 antigen expressed on 
the surface of human B-cells. By binding to the CD20 antigen it promotes 
antibody-dependent cell-mediated cytotoxicity and complement-dependent 
cytotoxicity and induces lysis and apoptosis of normal and malignant hu-
man B- cells. Furthermore, it sensitises malignant B-cells to the cytotoxic ef-
fect of chemotherapy [3, 4].  
The recommended treatment regimen consists of six treatment cycles of ri-
tuximab in combination with fludarabine and cyclophosphamide at inter-
vals of 28 days (= 1 cyle). Rituximab is administered only once at the begin-
ning of every cycle with an initial starting dose of 375mg/m2 body surface 
area (BSA) intravenously (IV) (Cycle 1), followed by 500mg/m2 IV (Cycle 2-
6) [2].  
Prior to start of therapy precautions, such as ensuring adequate hydration 
and administration of uricostatics, are recommended to reduce the risk of 
tumour lysis syndrome. In addition, for CLL patients whose lymphocyte 
counts are more than 25 x 109/L prednisone/prednisolone 100mg IV should 
be administered shortly before infusion of rituximab to decrease the rate and 
severity of acute infusion reactions and/or cytokine release syndrome [2]. 
Patients have to be monitored closely for onset of a cytokine release syn-
drome (CRS) with severe reactions, such as severe dyspnoea, bronchospasm 
or hypoxia, which require intermediate interruption of infusion. If symp-
toms resolve, the infusion of rituximab may be restarted at half of the previ-
ous rate [2]. 
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2 Indication 
Rituximab is indicated for the first-line treatment of patients with chronic 
lymphocytic leukaemia (CLL) in combination with chemotherapy [2].  
3 Burden of disease 
Chronic lymphocytic leukaemia (CLL) belongs to the entity of indolent B-
cell non-Hodgkin lymphomas (NHL) and is the most common adult leu-
kaemia in the Western World. It accounts for 40% of all leukaemias in indi-
viduals aged more than 65 years with men being affected twice as often as 
women.  The median age of presentation is 70 to 74 years [5]. 
Risk factors for developing CLL include older age, male sex, white ethnicity, 
family history of CLL or other blood and bone marrow cancers and exposure 
to certain chemicals, such as herbicides and insecticides [6].  
In the majority of cases CLL is diagnosed incidentally by routine complete 
blood count examination. Most patients are asymptomatic at the time of di-
agnosis. The most common symptom is lymphadenopathy, followed by so 
called “B” symptoms, including fever, night sweats and weight loss. The life 
expectancy of patients with early stage disease at diagnosis is greater than 
ten years but decreases with advanced disease at diagnosis to a median sur-
vival of less than one year [7-9]. 
According to the recently updated National Cancer Institute-Working 
Group 1996 guidelines for the diagnosis and treatment of chronic lympho-
cytic leukaemia [10], the diagnosis of CLL requires a B lymphocytosis of 
≥5.0 x 109/L with characteristic morphology and immunophenotype in the 
peripheral blood for at least three months [5, 10]. Interphase fluorescence-in 
situ hybridization (FISH) is recommended at diagnosis to identify cytoge-
netic lesions, such as deletion in the short arm of chromosome 17 (del(17p)) 
which is associated with resistance to standard chemotherapy regimens and 
poor prognosis [10].  
There are two classification systems for the clinical staging of CLL, depend-
ing on standard laboratory tests and physical examination, including the Rai 
classification and the Binet staging system. The Rai classification distin-
guishes low (formerly Rai stage 0), intermediate (formerly Rai stage I or II) 
and high (formerly Rai stage IV and V) risk disease, whereas the Binet stag-
ing is subdivided into stage A, B and C [10].  
The prognosis of CLL depends upon several factors und might be worsened 
by advanced disease stage, short lymphocyte doubling time, higher levels of 
beta‐2‐microglobulin,  absence  of  immunoglobulin  variable  region  heavy 
chain mutation, ZAP‐70 (zeta‐chain associated protein kinase 70) positivity, 
FISH chromosomal abnormalities and CD38 positivity [11].  
Standard treatment options for patients with CLL comprise watchful wait-
ing, radiation therapy, chemotherapy, corticosteroids, and monoclonal anti-
body therapy [11].  
CLL is the most common 
leukaemia in 
industrialised countries, 
and affects mainly men 
aged ≥70 years 
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The initiation of treatment is not recommended for asymptomatic early-
stage disease (Rai 0, Binet A). In these patients a watch-and-wait strategy 
with controls of blood cell counts and clinical examination every three to six 
months is recommended until there is evidence of disease progression. In 
patients with intermediate and high risk disease, according to the Rai classi-
fication as well as patients with Binet stage B or C disease, the initiation of 
treatment is recommended, whereas some patients with intermediate disease 
or Binet stage B might as well be monitored until disease progresses [9, 10]. 
Disease progression requiring treatment is based on certain criteria, such as 
increasing adenopathy, hepatosplenomegaly, development of auto-immune 
cytopenias, and marrow failure [5, 10]. 
Overall, the incidence of CLL seems to depend on the ethnicity with white 
males having the highest incidence of CLL of 6/100,000/year (y), followed 
by white females with an incidence of 3.1/100,000/y [12].  
In Austria the overall incidence of all forms of leukaemia (C91-C951 accord-
ing to the World Health Organization’s International Classification of Dis-
eases - 10 [13] was 7.3/100,000/y in 2006. Among males, the incidence was 
8.6/100,000/y, whereas among females it was 6.3/100,000/y in 2006. The 
overall death rate of all forms of leukaemia was 4.6/100,000/y in Austria in 
2006. Within men, the death rate was 5.9/100,000/y and within women it 
was 3.7/100,000/y in 2006 [14].  
In the United States the age-adjusted incidence of chronic lymphocytic leu-
kaemia in Whites was 6.23/100,000/y in males and 3.49/100,000/y in females 
in 2006 [12]. 
The incidence of CLL in Austria is expected to rise in the future due to an 
increasing elderly stratum of the population. 
4 Current treatment 
There are various treatment options for CLL depending on disease stage, pa-
tient’s age, presence of cytogenetic lesions, concomitant diseases and – with 
second line therapy – duration of response, including (ordered from the least 
to the most toxic options) [11] 
 Observation/watchful waiting 
                                                             
1 C91 = Lymphoid leukaemia + subtypes, one of which is CLL (C91.1); C92 = Mye-
loid leukaemia + subtypes; C93 = Monocytic leukaemia + subtypes; C94 = Other 
leukaemias of specified cell type + subtypes; C95 = Leukaemia of unspecified cell 
type + subtypes  
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 Oral alkylating agents (chlorambucil) with or without corticoster-
oids 
 Purine analogs (fludarabine, 2-chlorodeoxyadenosine, pentostatin) 
 Combination chemo(immuno)therapy (e.g. fludarabine + cyclo-
phosphamide (FC), cyclophosphamide + vincristine + prednisone 
(COP), cyclophosphamide + doxorubicin + vincristine + predni-
sone (CHOP), fludarabine + cyclophosphamide + mitoxantrone 
(FCM), bendamustine, besides others) 
 Involved-field radiation therapy 
 Radioimmunotherapy 
 Anti-CD52 monoclonal antibody (alemtuzumab) 
 Bone marrow and peripheral stem cell transplantations are cur-
rently under clinical evaluation in patients younger than 60 years 
with adverse prognostic factors 
The National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guidelines in Oncology [15] provide detailed information on current treat-
ment options for both first- and second-line therapy of CLL.  
5 Current regulatory status 
Rituximab (MabThera®) was approved by the European Medicines Agency 
(EMEA) [2]  
 for the first-line treatment of patients with CLL in combination 
with chemotherapy in January 2009.  
 for the treatment of NHL (first approval was granted in 1998 with 
subsequent extensions of indication), including  
 previously untreated patients with stage III-IV follicular 
lymphoma in combination with chemotherapy. 
 maintenance therapy of patients with relapsed/refractory 
follicular lymphoma responding to induction therapy with 
chemotherapy with or without rituximab. 
 monotherapy of patients with stage III-IV follicular lym-
phoma who are chemoresistant or are in their second or 
subsequent relapse after chemotherapy. 
 patients with CD20-positive, diffuse large B-cell NHL in 
combination with cyclophosphamide, doxorubicin, vincris-
tine, prednisolone (CHOP) chemotherapy. 
 in combination with methotrexate for adult patients with severe ac-
tive rheumatoid arthritis who have had an inadequate response or 
intolerance to other disease-modifying anti-rheumatic drugs includ-
ing one or more tumour necrosis factor inhibitor therapies in June 
2006.  
observation, 
chemotherapy, 
chemoimmunotherapy, 
involved-field radiation 
therapy, 
radioimmunotherapy, 
anti-CD52 monoclonal 
antibody, 
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In addition, the Committee for Medicinal Products for Human Use of the 
EMEA adopted a positive opinion to recommend MabThera® in combina-
tion with chemotherapy for the treatment of patients with relapsed/ refrac-
tory CLL  in  July 2009 [2]. 
 
In  Austria  off‐label  use  of  rituximab  include  refractory  autoimmune  cyto‐
penias, such as autoimmune haemolytic anaemia and idiopathic thrombocy‐
topenic purpura, as well as treatment of complications related to transplan‐
tation,  such  as  rejection  reaction,  Graft‐versus‐host‐disease,  and  post‐
transplant lymphoproliferative disorder, besides others.  
Rituximab (Rituxan®)  was  approved  by  the  United  States  Food  and  Drug 
Administration (FDA) [16] 
 for the treatment of NHL, including 
 relapsed/ refractory low‐grade or follicular CD20‐positive, 
B‐cell NHL as a single agent in November 1997. 
 previously  untreated  follicular,  CD20‐positive,  B‐cell  NHL 
in  combination  with  cyclophosphamide,  vincrinstine, 
prednisolone (CVP) chemotherapy in September 2006. 
 non‐progressing  (including  stable  disease),  low‐grade, 
CD20‐positive, B‐cell NHL as a  single agent after  first‐line 
CVP chemotherapy in September 2006. 
 previously untreated diffuse large B-cell, CD20-positive 
NHL in combination with CHOP or other anthracycline-
based chemotherapy regimens in October 2006. 
 in  combination with methotrexate  to  reduce  the  signs  and  symp‐
toms  in adult patients with moderately  ‐  to severely  ‐ active rheu‐
matoid  arthritis  who  have  had  an  inadequate  response  to  one  or 
more tumour necrosis factor antagonist therapies in February 2006. 
In  addition,  the  manufacturers  submitted  two  supplemental  Biologics  Li‐
cense Applications to FDA concerning treatment with rituximab in combina‐
tion with standard chemotherapy for patients with previously treated or un‐
treated lymphocytic leukaemia in May 2009 [17]. 
6 Evidence 
To date, no randomised controlled trials concerning the first- and second-
line treatment of CLL with rituximab, fludarabine and cyclophophamide 
(FCR) have been fully published in peer-reviewed journals [18]. Neverthe-
less, there are two completed phase III trials (as shown in section 6.1) which 
assessed the combination of FCR compared to fludarabine and cyclophos-
phamide (FC) in patients with both previously untreated, active CLL and 
patients with relapsed or refractory CLL [19]. The results of these two trials 
were initially presented at the American Society of Hematology annual 
meeting in December 2008. In addition, several phase II trials (described in 
EMEA issued a positive 
opinion concerning 
second-line therapy of 
CLL with rituximab 
off-label use in Austria 
for autoimmune 
cytopenias, 
complications of 
transplantation, besides 
others  
FDA approval for non-
Hodgkin lymphomas 
and rheumatoid arthritis 
FDA supplemental 
Biologics License 
Applications for first- 
and second-line 
treatment of CLL 
two phase III studies 
were conducted 
concerning the first- and 
second-line treatment 
of CLL with rituximab in 
combination with 
chemotherapy but have 
not been published in 
peer-reviewed journals 
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section 6.2) have assessed the combination of FCR in the first- and second-
line treatment of CLL.  
Overall, it is important to note that the biologic and clinical heterogeneity of 
CLL makes it difficult to compare and extrapolate the results of clinical tri-
als [20].  
6.1 Efficacy and safety - Phase III studies 
Table 1: Phase III studies of rituximab for the first- and second-line treatment of CLL 
Reference  CLL-8 / ML17102 Protocol of the German CLL
Study Group (GCLLSG) – completed, to be
published [2, 19, 21-24] 
EUDRACT-2004-004938-14 
ISRCTN02757147 
NCT00281918 
REACH trial / BO17072 – completed, to be 
published [19, 21, 25, 26] 
 
 
NCT00090051 
 
Sponsor Hoffmann-La Roche Ltd, Basel, Switzerland  
 
Biogen Idec. 
Collaborators: Hoffmann-La Roche, Genen-
tech 
Country Multicentre – International (190 study sites 
across 11 countries) 
Multicentre – International (88 study sites 
across 17 countries) 
Design Prospective, randomised, open-label, active 
control 
(Randomisation stratified by country and dis-
ease stage according to the Binet staging sys-
tem), crossover (patients with stable disease 
or progressive disease after three cycles of 
treatment were withdrawn from study 
treatment and eligible to receive alternative 
treatment, including rituximab-containing 
regimens) 
Randomised, open-label , active control  
Participants  
characteristics 
n=817 patients (pts) (I: 408 vs. C: 409); me-
dian age I: 61y (30-80y), C: 61y (36-81y);  
n=552 patients (pts) (I:276 vs. C:276); median 
age I: 63y (35-83y), C: 62y (35-81y);  
Treatments I(ntervention): Rituximab +Fludarabine + 
Cyclophosphamide for a total of six treatment 
cycles at intervals of 28 days 
Rituximab IV infusion before FC infusion  
Cycle 1: 375mg/m2 IV; d0 
Cycle 2-6 : 500mg/m2 IV ; d1 
Fludarabine IV infusion over three days for six 
treatment cycles (25mg/m2/day IV; d1-d3) 
Cyclophosphamide IV infusion over three 
days for six treatment cycles (250mg/m2/day 
IV; d1-d3)  
 
C(ontrol): Fludarabine + Cyclophosphamide 
Fludarabine IV infusion over three days for six 
treatment cycles (25mg/m2/day IV; d1-d3) 
Cyclophosphamide IV infusion over three 
days for six treatment cycles (250mg/m2/day 
IV; d1-d3)  
I(ntervention):Rituximab + Fludarabine + 
Cyclophosphamide for a total of six treatment 
cycles at intervals of 28 days 
Rituximab IV infusion before FC infusion 
Cycle 1: 375mg/m2 IV; d0 
Cycles 2-6: 500mg/m2 IV; d1 
Fludarabine IV infusion over three days for six 
treatment cycles (25mg/m2/day IV; d1-d3) 
Cyclophosphamide IV infusion over three 
days for six treatment cycles (250mg/m2/day 
IV; d1-d3)  
 
C(ontrol): Fludarabine + Cyclophosphamide 
Fludarabine IV infusion over three days for six 
treatment cycles(25mg/m2/day IV; d1-d3) 
Cyclophosphamide IV infusion over three 
days for six treatment cycles (250mg/m2/day 
IV; d1-d3)     
In-/exclusion criteria Inclusion criteria: Patients with untreated, ac-
tive B-cell CLL and good physical fitness 
(CIRS1 score ≤6), Binet stage B and C requir-
Inclusion criteria: relapsed or refractory pa-
tients with B-cell CLL and ≤one previous 
chemotherapy, Binet stages A, B, C, ECOG2 
                                                             
1 CIRS = Cumulative Illness Rating Scale 
2 ECOG = Eastern Cooperative Oncology Group 
CLL is biologically and 
clinically heterogeneous 
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ing treatment (certain criteria have to be ful-
filled), age ≥18 years, expected survival >6 
months, EC OG2 performance status 0-1  
 
Exclusion criteria: Binet stage A, prior chemo-
therapy and/or radiotherapy, clinically signifi-
cant auto-immune cytopenia, Coombs-
positive haemolytic anaemia as judged by the 
treating physician  
Performance Status 0-1, age ≥18 years, ex-
pected survival >6 months, acceptable hema-
tologic status, liver function, renal function 
and pulmonary function  
Exclusion criteria: prior treatment with Inter-
feron, rituximab or other monoclonal anti-
body, prior allogeneic or autologous bone 
marrow transplant or peripheral stem cell 
transplant or patients who are considered to 
be candidates for those procedures as as-
sessed by their treating physicians, severe 
grade 3 or 4 non-hematological toxicity or 
prolonged (>2 weeks) grade 3 or 4 cytopenia 
on prior fludarabine or nucleoside analogue 
regimen, history of fludarabine-induced or 
clinically significant autoimmune cytopenia  
Follow-up Median follow-up 25.4 months Median follow-up 25.3 months 
Outcomes Primary:  Progression-free survival (PFS) 
 
Secondary: Overall survival (OS), response 
rates, rates of treatment-related adverse ef-
fects  
Primary:  Progression-free survival (PFS) 
 
Secondary: Overall survival (OS), response 
rates 
 
Key results  
 
Primary:  
Median PFS at 25.4 months: I: 42.8 months 
vs. C: 32.5 months (p<0.001), HR3= 0.60 
(95% CI4 0.48 – 0.76; p<0.001) 
PFS at 25.5 months: I: 76.6% vs. C: 62.3% 
(p<0.001) 
PFS at 26.4 months: I: 37.1 months vs. C: 30.8 
months (p<0.001), HR=0.6 (95% CI 0.47 – 
0.75; p<0.0001) 
 
Secondary: 
OS at 25.4 months: HR=0.72 (95% CI: 0.48, 
1.09; p=0.13), at 25.5. months I: 91% vs. C: 
88% (p=0.18);  
Mean OS at 26.4 months: I: 47.7 months vs. C:
48.2 (p=0.18) 
Response to treatment: Overall response rate 
I: 95% vs. C: 88% [p=0.001]; complete remis-
sion I: 44.5% vs. C: 22.9% [p<0.01]; partial 
remission I: 39.6% vs. C: 50.4% [p<0.01], 
progressive disease I: 3.3% vs. C: 8.1% 
[p<0.01] 
Primary:  
Median PFS: I: 30.6 months vs. C: 20.6 
months [p=0.0002], HR3= 0.65 (95% CI4: 
0.51, 0.82)   
 
 
 
 
 
 
Secondary: 
Median OS: I: not reached vs. C: 51.9 months 
 
 
 
 
Response to treatment: Overall response rate 
I: 69.9% vs. C: 58.0% (p=0.0034); complete 
remission I: 24.3% vs. C: 13.0% [p=0.0007]; 
partial remission I: 45.7% vs. C: 44.9%; pro-
gressive disease I: 2.5% vs. C: 5.4%    
 
Adverse effects Grade 3/4 CTC5 adverse events (I vs. C) 
 
Overall: 309 (77.5%) vs. 248 (62.6%) 
[p<0.0001]; Hematological toxicity 55.7% vs. 
39.4% [p<0.0001] Neutropenia 33.7% vs. 
21% [p<0.0001] 
Leukocytopenia 24% vs. 12.1% [p<0.0001]  
Thrombocytopenia 7.4% vs. 10.9% 
Anemia 5.4% vs. 6.8%  
Infection 18.8% vs. 14.9%  
Tumour Lysis Syndrome 0.2% vs. 0.5% 
Cytokine release syndrome 0.25% vs. 0.0% 
Treatment related mortality 2.0% vs. 1.5% 
Grade 3/4 CTC5 adverse events (I vs. C) 
 
Overall: 65pts (23.6%) vs. 60pts (21.7%)  
Infusion-related (d1-2 of first cycle): 6pts 
(2.2%) vs. 4pts (1.5%) 
Tumour Lysis Syndrome: 2pts (0.7%) vs. 3pts 
(1.1%) 
Neutropenia 42pts (15.2%) vs. 40pts (14.5%)
Febrile Neutropenia: 15pts (5.4%) vs. 12pts 
(4.3%) 
Thrombopenia: 11pts (4%) vs. 9pts (3.3%) 
Autoimmune haemolytic anaemia: 5pts 
(1.8%) vs. 12pts (4.3%) 
Infections: 17pts (6.2%) vs. 19pts (6.9%) 
                                                             
3 HR = Hazard Ratio 
4 CI = Confidence Interval 
5 CTC = Common Terminology Criteria 
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Hepatitis B: 2pts (0.7%) vs. 0 pts (0%) 
Benign or malignant neoplasms: 7pts (2.5%) 
vs. 3pts (1.1%)  
Commentary 7 pts. were excluded from all analyses due to 
missing informed consent. The ITT6 popula-
tion included 810 pts. (I: 403 vs. C: 407) 
 
As shown in multivariate analyses certain fac-
tors, including age, gender, Binet stage, CIRS 
score and renal function, were independently 
predicting PFS or OS. 
 
                                                             
6 ITT = Intention To Treat 
 
Two phase III trials with a median follow-up of about 25 months have been 
conducted comparing FCR versus FC in patients both with previously un-
treated, active B-cell CLL and patients with relapsed/refractory B-cell CLL. 
Although both trials showed a significantly increased overall response rate, 
complete remission rate and progression-free survival in the FCR arm com-
pared to the FC arm, there was no difference in overall survival between the 
intervention and control group. In terms of grade 3/4 adverse events, pa-
tients in the intervention group compared to the control group of CLL-8 
were significantly more often affected by haematological toxicity, particu-
larly neutropenia and leukocytopenia, even though no increased rates of in-
fections were observed. 
6.2 Efficacy and safety - further studies 
Tam et al. [27] compared long-term results of a FCR regimen in 300 patients 
with previously untreated, active CLL in an open-label phase II trial with a 
historical comparison of 190 patients who had received other active treat-
ments, such as fludarabine ± prednisone, fludarabine and cyclophosphamide 
or fludarabine and mitoxantrone. They concluded that the FCR regimen 
yielded the highest rates of complete remission, longest remission duration 
and most favourable survival. After a median follow-up of six years the over-
all survival was 77% and the failure2-free survival was 51%. Of note, data 
concerning the historical comparison group was not presented by the au-
thors. The median age of patients in this study was 57y and only 14% of pa-
tients were aged 70 years or more. In addition, almost two thirds of patients 
were suffering from low and intermediate risk disease according to the Rai 
classification and only one third of patients were classified as having high 
risk disease. Both, complete remission rate and survival, were independently 
associated with age younger than 70 years, white cell count less than 150 x 
109/L, absence of chromosome 17 abnormalities and beta-2-microglobulin 
less than twice the normal limit. In terms of adverse events, advanced Rai 
stage was associated with an increased risk of persistant cytopenia (>3 
months) following completion of FCR therapy.  
                                                             
2 Failure was defined as primary refractory disease, CLL progression (including de-
velopment of Richter transformation), therapy-related myelodysplasia, or death. 
median follow-up 25 
months, no difference in 
overall survival between 
intervention and control 
group, grade 3/4  
neutropenia and 
leukocytopenia occurred 
more often in the 
intervention arm 
compared to the control 
arm  
FCR compared to other 
treatments, six year 
follow-up, historical 
comparison; no data on 
comparators provided 
median age 57y, low and 
intermediate risk disease 
in two thirds of patients 
 
 LBI-HTA | 2009 11 
Keating et al. [28] conducted a single-arm study of FCR in 224 patients with 
previously untreated, active CLL and concluded that FCR leads to a high 
rate of complete remission (70%). Nevertheless, the median age of patients 
enrolled was 58 years with only 13% of patients being 70 years or older. Fur-
thermore, slightly more than two thirds of patients were suffering from low 
and intermediate risk disease according to the Rai classification and only 
one third of patients were classified as having high risk disease. 26% of pa-
tients did not complete six courses of therapy, mainly due to persistant cyto-
penia. Early discontinuation was significantly associated with advanced dis-
ease stage, older age, anaemia, impaired renal function and elevated beta-2-
microglobulin levels.  
Wierda et al. [29] retrospectively compared three sequential groups of pa-
tients with recurrent or refractory CLL treated with fludarabine 
±prednisone (n=251), FC (n=111) or FCR (n=143). Among those three 
groups, the longest estimated median survival was observed for patients who 
received FCR.  
Tam et al. [30] assessed the FCR regimen for the treatment of patients with 
CLL or indolent NHL in an observational series. 77 patients with a median 
age of 59 years, of whom 34 were suffering from CLL - 12 of whom were suf-
fering from previously untreated CLL - were treated with FCR. 18 of the 34 
patient were classified low or intermediate risk disease according to the Rai 
classification. The FCR regimen yielded a high rate of complete remission 
and prolonged disease remissions. It is important to note, however, that this 
study assessed a small group of patients with heterogeneous characteristics 
in terms of age, disease, disease stage and previous treatments which com-
plicates an extrapolation of results.   
Foon et al. [31] conducted a single-arm study of FCR in 48 patients with 
previously untreated CLL with a median age of 58 years, 83% of whom had 
low and intermediate risk disease according to the Rai classification. This 
study aimed at reducing the rate of grade 3/4 neutropenia by decreasing the 
dose of fludarabine and cyclophosphamide and increasing the dose of ri-
tuximab (FCR-Lite). Although grade 3/4 neutropenia could be reduced 
dramatically, an impact of FCR-Lite on overall survival has not been estab-
lished yet which will be of utmost importance concerning the higher treat-
ment costs, if rituximab is added at increased doses.  
The study by Lamanna et al. [32], so far the only one which focused on pa-
tients with intermediate or high risk CLL, explored a sequential therapy 
with fludarabine, followed by cyclophosphamide and rituximab in 36 pa-
tients with a median age of 59 years with previously untreated CLL. They 
concluded that sequential treatment with FCR is superior to sequential 
treatment with FC in terms of improved quality of response. However, a se-
quential therapy of FCR has not yet been compared to the concomitant 
regimen of FCR in prospective randomised controlled trials. 
Further studies assessed various regimens and combinations of rituximab, 
such as modified FCR regimens for CLL [33], new chemoimmunotherapy 
combinations for previously treated and untreated CLL [34-38], consolida-
tion and maintenance immunotherapy with rituximab in patients with CLL 
[39], the addition of rituximab to fludarabine in patients with previously un-
treated CLL [40] and previously untreated ZAP-70 negative CLL [41]. 
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7 Estimated costs 
In Austria rituximab is marketed by Roche Austria, Vienna. One package of 
100mg rituximab (10mg/ml) concentrate for solution for infusion consisting 
of two single-use vials is € 616.15. In addition, one package of 500mg rituxi-
mab (10mg/ml) concentrate for solution for infusion containing one single-
use vial is € 1,492.75 [42].  
Assuming an average body surface area, based on height and weight, of 1.7 
m2 for both men and women, total treatment costs for the recommended ri-
tuximab regimen can be estimated. The first cycle of rituximab infusion 
would be € 2,109, followed by € 2,725 for cycle two to six (assuming that two 
packages containing two 100mg vials are used) which would add up to total 
treatment costs of € 15,734 in addition to chemotherapy.   
8 Ongoing research 
There are a number of ongoing phase III trials of rituximab [21], such as 
 NCT00769522: German CLL study group, Germany; CLL first-line 
therapy; primary outcome: progression-free survival; results ex-
pected 2018. 
 NCT00645606: GOELAMS and FCGCLL/WM, France; CLL 
maintenance; primary outcome: progression-free survival; results 
expected 2012. 
There are several ongoing phase II trials assessing the effectiveness of ri-
tuximab in combination with various chemotherapy regimens for the treat-
ment of previously untreated as well as relapsed/refractory CLL. In addi-
tion, rituximab is intensively investigated as maintenance therapy in CLL 
and other NHLs. Multiple second generation antibodies, such as ofatumu-
mab, are under clinical development for the treatment of CLL as well. Fur-
thermore, there are numerous phase II trials exploring the use of rituximab 
in different diseases, such as acute thrombotic thrombocytopenic purpura, 
multiple sclerosis, progressive sarcoidosis, and rheumatoid arthritis, besides 
others [43].  
In Austria the Arbeitsgemeinschaft Medikamentöse Tumortherapie [44] is 
currently conducting a phase II trial (CLL-5 RevliRit) assessing fludara-
bine/rituximab in combination with lenalidomide, followed by rituxi-
mab/lenalidomide for the first-line treatment of CLL. Results are expected 
in 2011. 
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9 Commentary - English 
CLL is the most common leukaemia in adults in industrialised countries 
and despite several treatment options still considered incurable except in a 
small group of patients eligible for allogeneic bone marrow transplantation. 
In addition to available treatment regimens, rituximab was approved by the 
EMEA for the first-line treatment of CLL patients in combination with che-
motherapy. Moreover, a positive opinion concerning the second-line treat-
ment of CLL patients in combination with chemotherapy has been issued by 
the EMEA in July 2009 [2].  
The CLL-8 trial demonstrated favourable outcomes in terms of PFS and 
complete remission rates for patients receiving FCR over patients receiving 
FC. In spite of encouraging results regarding improved overall survival in an 
interim analysis, the study failed to maintain this advantage during follow-
up, but the authors [24] argue that this might have been due to subsequent 
lines of treatment as well as cross-over. The incidence of grade 3/4 adverse 
events, mainly haematological reactions occuring particularly during the 
first treatment cycles, was higher in the intervention than in the control 
group. Moreover, serious adverse events, the most common of which was 
febrile neutropenia, were observed in 46% of the FCR arm and in 41% in 
the FC arm. However, the percentage of deaths judged to be related to treat-
ment was 2% in FCR and 1.5% in FC [2].  
The choice of treatment regimen for CLL depends upon several factors, such 
as patient’s age, disease stage, presence of cytogenetic lesions, concomitant 
diseases and - with second-line treatment – duration of response [11].  Che-
motherapy mainly provides a treatment option for patients aged less than 70 
years and in good clinical condition [15]. With Rituximab in combination 
therapy response rates increased by about 10%, PFS by 7 to 10 months, no 
effect on OS has been proven yet. As response rates and progression-free 
survival are believed to lead to a substantial gain in quality of life (while the 
effect from PFS on increased overall survival is under debate), FCR might 
be a treatment option for those patients but at the expense of increased tox-
icity. In contrast, as the majority of patients are diagnosed at the age of 70 or 
above, only a limited number of CLL patients might be suitable for this 
treatment. Of note, the trials presented in this report included mainly 
younger and fitter patients, making it difficult to judge possible positive and 
negative consequences for older individuals.  
Overall, the chosen study populations as well as the comparator (FC only) in 
the two phase IIl studies seem to be appropriate for the intended target 
group but the study populations were younger and fitter than CLL patients 
in clinical practice [24]. Therefore, to assess the value of rituximab in older 
individuals with comorbidities who make up the majority of CLL patients, 
further trials both in comparison to and in combination with chlorambucil 
and other less aggressive regimens than FC are needed. Furthermore, ri-
tuximab is a potential add-on to any other CLL chemotherapy regimen 
other than FC because most of the FCR toxicity is caused by the FC part of 
the schedule.  
Because rituximab is an add-on to existing CLL treatment regimens and 
CLL is on the rise in Austria due to an ageing population, the financial im-
pact of the licensure of rituximab for the treatment of CLL will be substan-
tial.      
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10 Commentary – German 
Die chronisch lymphatische Leukämie ist die häufigste Form der Leukämie 
Erwachsener in industrialisierten Ländern und wird trotz zahlreicher Be-
handlungsoptionen, mit Ausnahme einer kleinen Gruppe von PatientInnen, 
die für eine allogene Transplantation qualifiziert, als nicht heilbar erachtet. 
Zusätzlich zu bereits verfügbaren Behandlungsregimes wurde Rituximab 
von der EMEA für die first-line Therapie von CLL-PatientInnen in Kombi-
nation mit Chemotherapie zugelassen. Außerdem erfolgte eine positive 
Empfehlung bezüglich der second-line Therapie von CLL-PatientInnen mit 
Rituximab in Kombination mit Chemotherapie durch die EMEA im Juli 
2009 [2]. 
Die CLL-8 Studie zeigte einen Vorteil bezüglich progressionsfreien Überle-
bens von PatientInnen, die FCR erhielten, im Gegensatz zu jenen, die FC 
verabreicht bekamen. Eine in einer  vorzeitig durchgeführten Datenanalyse 
erhobene verbesserte Überlebensrate im FCR Arm, konnte im weiteren Ver-
lauf nicht bewiesen werden, wobei dies von den Autoren [24] auf nachfol-
gende Therapien sowie cross-over im FC Arm zurückgeführt wird. Die Inzi-
denz Grad 3/4 unerwünschter Nebenwirkungen, vor allem hämatologischer 
Natur, die vorwiegend in den ersten Therapiezyklen auftraten, war in der 
Interventionsgruppe höher als in der Kontrollpopulation. Schwerwiegende 
unerwünschte Nebenwirkungen, von denen die häufigste die febrile Neutro-
penie darstellte, traten bei 46% der PatientInnen im FCR Arm und bei 41% 
der PatientInnen im FC Arm auf. Der prozentuelle Anteil der Todesfälle, 
welche mit der Therapie in Verbindung gebracht wurden, betrug zwei Pro-
zent im FCR Arm und 1.5%  im FC Arm [2].  
Die Wahl der jeweiligen Behandlungsmethode für CLL PatientInnen hängt 
von mehreren Faktoren, wie dem Alter der Patientin/des Patienten, dem 
Stadium der Erkrankungen, dem Vorhandensein zytogenetischer Läsionen, 
der Komorbidität und – im Falle der second-line Therapie –der Dauer der 
Remission, ab [11]. Chemotherapie stellt hauptsächlich eine Behandlungs-
option von PatientInnen unter 70 Jahren dar, die sich in einem guten All-
gemeinzustand befinden [15]. Mit Rituximab als Kombinationstherapie er-
höhte sich die Remissionsrate um circa 10%, und progressionsfreies Überle-
ben verlängerte sich um sieben bis zehn Monate, jedoch konnte eine Verlän-
gerung des Gesamtüberlebens nicht bewiesen werden. Da man davon aus-
geht, dass Remission und progressionsfreies Überleben zu einer beträchtli-
chen Verbesserung der Lebensqualität führen (wobei der Effekt des verlän-
gerten progressionsfreien Überlebens auf das Gesamtüberleben derzeit noch 
diskutiert wird), könnte FCR einen wertvollen Beitrag zu bestehenden Be-
handlungsmethoden liefern, jedoch mit dem Nachteil einer erhöhten Toxi-
zität. Auf der anderen Seite ist der Großteil der PatientInnen bei Diagnose-
stellung  ≥ 70 Jahre alt, wodurch ohnehin nur ein kleiner Anteil an CLL Pa-
tientInnen für diese Therapie in Frage kommen würde. Von Interesse ist, 
dass die hier präsentierten Studien hauptsächlich jüngere PatientInnen in 
gutem Allgemeinzustand inkludierten, sodass es schwierig ist, daraus Rück-
schlüsse auf ältere Personen zu ziehen.  
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Zusammenfassend scheinen die gewählten Studienpopulationen sowie die 
Kontrolle (FC) der beiden Phase III Studien zwar angemessen für die Ziel-
population gewesen zu sein, die StudienteilnehmerInnen waren jedoch jün-
ger und befanden sich in besserem Allgemeinzustand als CLL PatientInnen 
in der klinischen Praxis [24]. Um den Nutzen von Rituximab für ältere Per-
sonen mit Begleiterkrankungen, welche den überwiegenden Teil der CLL 
PatientInnen ausmachen, bewerten zu können, wären weitere Studien im 
Vergleich zu beziehungsweise in Kombination mit Chlorambucil und ande-
ren weniger aggressiven Regimes als FC wünschenswert.  
Rituximab stellt eine potentielle Erweiterung jeder CLL Chemotherapie 
neben FC dar, umsomehr als der größte Teil der FCR Toxizität durch den 
FC Teil des Regimes bedingt ist.  
Da der Einsatz von Rituximab in der Therapie der CLL eine additive Erwei-
terung existierender Behandlungskonzepte darstellt und die CLL in Öster-
reich im Zunehmen begriffen ist, müssen die finanziellen Auswirkungen  
der Zulassung von Rituximab zur Behandlung der CLL als gravierend ein-
geschätzt werden.   
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